A network meta-analysis compared GLP-1 receptor agonists to traditional anti-diabetes drugs based on hypoglycemia incidence, HbA1c goals, and more.
© Kim Reinick/Shutterstock.com
GLP-1 Agonists: Beneficial in Low-Risk Patients?
Do low-risk CVD patients with T2DM experience the same significantly lower all-cause and CV mortality seen in high-risk patients?
Can Liraglutide Delay Diabetes Onset?
Researchers compared time to onset of diabetes in a group of patients with obesity and pre-diabetes treated with liraglutide or placebo.
Interesting T2DM: Diabetic Retinopathy & Drug News
Our February list includes a newly approved drug combo, the ADA’s position statement on diabetic retinopathy, and lifestyle intervention studies.
Combo Therapy vs Insulin: Type 2 Diabetes
The Qatar Study investigated the efficacy of exenatide plus pioglitazone versus basal-bolus insulin in poorly-controlled type 2 diabetes.
Interesting T2DM: Peds Obesity & AHA Guides
Our February list includes updated guidelines for pediatric obesity, American Heart Assoc. statement on meal timing & frequency, and diabetes risks.
Diabetes Control: Insulin, Metformin & Exenatide
How do you treat patients with type 2 diabetes unable to achieve glycemic control with either oral treatment or basal insulin?
Top 10: Endocrinology Network 2016
SGLT2 inhibitors, GLP-1 receptor agonists, insulin, and more – we’ve compiled a list of this year’s most popular articles on Endocrinology Network.
Interesting T2DM: Psychosocial Care & CV, DM Risk
Our December list includes new care guidelines from the ADA, a new indication for an SGLT2i, and effects of PCI on CV, DM risk.
By clicking Accept, you agree to become a member of the UBM Medica Community.